BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), an advanced digital signal processing technology
company delivering unprecedented accuracy and precision to
intracardiac signal visualization with its proprietary PURE EP™
System, today announced the appointment of new Advisory Board
member Edwin Wang.
Mr. Wang has over 20 years of impactful experience in private
equity, venture capital, merchant banking, and family office
investing. He is the founder of Accretive Capital Partners LLC, a
pioneering direct investment sponsor in middle market private
equity that raised, invested and harvested a top quartile secondary
direct investment fund, Accretive Exit Capital Partners LP, with
seasoned limited partners HarbourVest Partners, Goldman Sachs
Vintage Funds, and Paul Capital Partners. Accretive Capital
Partners has advised in excess of $2 billion in portfolio and fund
restructurings.
Earlier, while at predecessor affiliate Asymmetry Capital LLC,
Mr. Wang led the successful financial restructuring and liquidation
of $1 billion in venture capital portfolios from Zero Stage Capital
whose legacy spawned a forerunner to Moderna. These accomplishments
were chronicled in several Harvard Business School case studies and
other publications, including The Deal Magazine. Previously,
following an eight-year investment banking career at Credit Suisse
and Lehman Brothers, he led the formation of Asia Corporate
Partners Fund, among the very first institutional direct investment
fund products for China anchored by CalPERS, CalSTRS, Capital
Group, China Development Bank (Taiwan), (whose core holdings
included Hon Hai Precision (Foxconn), Taiwan Semiconductor
Manufacturing and Texas Instruments/Acer) along with other leading
global asset managers.
Mr. Wang earned his B.A. in Economics from Columbia University
and was a Visiting Fellow in Finance at the MIT Sloan School of
Management at the invitation of the late Nobel laureate in
Economics, Dr. Franco Modigliani.
“Edwin Wang is a highly regarded and well-connected investment
strategist with many years of experience in global capital markets,
including a storied record of success in private equity growth
capital and technology investing,” said Ken Londoner, Chairman, CEO
and Founder of BioSig. “He will be an excellent resource for our
capital markets strategy and targeted expansion of our shareholder
base. We warmly welcome Ed to our advisory team.”
“Ken Londoner is a seasoned entrepreneur who blends
strategic vision, technical brilliance and solid execution – a rare
combination in the intersection of finance and industry – and I am
excited to help support him and the team at BioSig “ said Edwin
Wang “Over the past quarter century, I have made numerous
investments in technology enabled healthcare companies, several of
which have had a profound impact on medicine and public
health. (Cardiovascular disease has been the leading cause of
death for too long with annual direct costs in the U.S. alone
estimated to be $109B*.) BioSig Technologies leads the way
forward in digital signal processing and AI for the treatment of
cardiac arrhythmias. I am humbled to be a part of this
critical mission to improve patient outcomes and save lives!”
* Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease
and stroke statistics—2018 update: a report from the American Heart
Association. Circulation. 2018;137:e67–e492.
Edwin Wang
About BioSig TechnologiesBioSig Technologies is
an advanced digital signal processing technology company bringing
never-before-seen insights to the treatment of cardiovascular
arrhythmias. Through collaboration with physicians, experts, and
healthcare leaders across the field of electrophysiology (EP),
BioSig is committed to addressing healthcare’s biggest priorities —
saving time, saving costs, and saving lives.
The Company’s first product, the PURE EP™ System, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform insight-based,
highly targeted cardiac ablation procedures with increased
procedural efficiency and efficacy.
The PURE EP™ System is currently in a national commercial launch
and an integral part of well-respected healthcare systems, such as
Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic,
and Kansas City Heart Rhythm Institute. In a blinded clinical
study recently published in the Journal of Cardiovascular
Electrophysiology, electrophysiologists rated PURE EP™ as
equivalent or superior to conventional systems for 93.6% of signal
samples, with 75.2% earning a superior rating.
The global EP market is projected to reach $16B in 2028 with an
11.2% growth rate.1
Forward-looking Statements This press release
contains "forward-looking statements." Such statements may be
preceded by the words "intends," “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Global Market Insights Inc. March 08, 2022.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road, 1st Floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024